FREAMINE III 8.5% W/ ELECTROLYTES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FREAMINE III 8.5% W/ ELECTROLYTES (FREAMINE III 8.5% W/ ELECTROLYTES).
FREAMINE III 8.5% W/ ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue maintenance in patients unable to tolerate oral/enteral nutrition.
| Metabolism | Amino acids undergo hepatic metabolism via transamination, deamination, and the urea cycle; eliminated primarily as urea and ammonia excreted by the kidneys. |
| Excretion | Renal (primarily as urea and ammonia); 100% of infused amino acids are metabolized or excreted renally. Fecal excretion negligible. |
| Half-life | Not applicable as a composite mixture; individual amino acid half-lives vary from minutes to hours. Clinical context: continuous infusion used for metabolic support. |
| Protein binding | Negligible; individual amino acids have variable binding (<10% for most). |
| Volume of Distribution | Not applicable as a mixture; individual amino acids distribute into total body water (~0.5–0.7 L/kg). Clinical meaning: rapid equilibration with extracellular and intracellular compartments. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (within minutes) as amino acids enter systemic circulation and are available for protein synthesis. |
| Duration of Action | Intravenous: duration of infusion-dependent; clinical effect sustained while infusion continues. Post-infusion, amino acid levels decline rapidly (minutes to hours). |
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (equivalent to 12-18 mL/kg/day of 8.5% solution). Administer via central or peripheral line. Typical adult dose: 500-1000 mL/day infused at 125-200 mL/hour.
| Dosage form | INJECTABLE |
| Renal impairment | Adjust based on GFR: GFR >50 mL/min: no adjustment; GFR 10-50 mL/min: reduce dose to 0.5-1.0 g amino acids/kg/day; GFR <10 mL/min: 0.3-0.5 g amino acids/kg/day. Monitor BUN and electrolytes. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce to 0.5-0.8 g amino acids/kg/day; Class C: contraindicated or use specialized amino acid formulation. Monitor ammonia levels. |
| Pediatric use | Neonates and infants: 2-3 g amino acids/kg/day IV; children: 1.5-2.5 g/kg/day. Use central line for concentrations >5%. Adjust based on age and clinical status. |
| Geriatric use | Elderly patients: start at lower end of dosing range (1.0 g/kg/day) due to decreased renal function and muscle mass. Monitor renal function, fluid balance, and electrolytes closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FREAMINE III 8.5% W/ ELECTROLYTES (FREAMINE III 8.5% W/ ELECTROLYTES).
| Breastfeeding | It is not known whether the components of FREAMINE III 8.5% W/ ELECTROLYTES are excreted in human milk. The M/P ratio has not been established. However, amino acids and electrolytes are normal constituents of breast milk. Caution should be exercised when administered to a breastfeeding woman; potential benefits should outweigh risks. Monitoring infant for signs of electrolyte imbalance is recommended if maternal therapy is prolonged. |
| Teratogenic Risk | FREAMINE III 8.5% W/ ELECTROLYTES is a parenteral nutrition solution containing amino acids and electrolytes. There are no adequate and well-controlled studies in pregnant women. In animal studies, intravenous amino acid solutions have not been associated with teratogenicity. However, electrolyte imbalances such as hyperkalemia or hypokalemia may pose risks to fetal development if maternal homeostasis is disrupted. First trimester exposure is unlikely to cause structural anomalies, but careful monitoring of maternal electrolyte and metabolic status is essential throughout pregnancy. Second and third trimester risks relate to maternal metabolic derangements rather than direct fetal effects. |
■ FDA Black Box Warning
This product is contraindicated in patients with inborn errors of amino acid metabolism, severe hepatic failure, or hepatic coma. Risk of metabolic acidosis, hyperammonemia, and azotemia if administered improperly. Use only under medical supervision with monitoring of plasma amino acid levels.
| Serious Effects |
["Hypersensitivity to any component","Severe hepatic failure or hepatic coma","Inborn errors of amino acid metabolism (e.g., phenylketonuria, maple syrup urine disease)","Severe azotemia not due to protein deficiency","Uncorrected electrolyte imbalances","Metabolic acidosis"]
| Precautions | Monitor renal function, hepatic function, and plasma electrolytes. Risk of volume overload in cardiac/renal impairment. Pulmonary embolism and thrombophlebitis from central line administration. Aluminum toxicity in renal impairment. Do not administer without added electrolytes unless specifically indicated. |
| Food/Dietary | No direct food interactions, but the solution is used in parenteral nutrition; oral intake should be managed according to the patient's nutritional plan. Avoid excessive oral intake of electrolytes (e.g., potassium, sodium) unless prescribed. Consult with dietitian. |
Loading safety data…
| Fetal Monitoring | Maternal monitoring: Serum electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate), blood glucose, serum osmolality, acid-base status, renal function (BUN, creatinine), liver function tests, and plasma amino acid levels. Fetal monitoring: Standard obstetric monitoring for maternal metabolic stability, including fetal heart rate monitoring and ultrasound for growth if prolonged therapy, especially in the setting of maternal complications like hyperglycemia or electrolyte disturbances. |
| Fertility Effects | No human data exists regarding effects of FREAMINE III 8.5% W/ ELECTROLYTES on fertility. Animal reproduction studies have not been conducted with this specific preparation. Uncontrolled electrolyte imbalances, particularly hyperkalemia or hypokalemia, may theoretically impair ovulatory function or spermatogenesis, but this is not specifically documented. |
| Clinical Pearls | FREAMINE III 8.5% with Electrolytes is a hypertonic amino acid solution (approx. 850 mOsm/L) for central venous administration only; peripheral infusion requires dilution to <600 mOsm/L to avoid thrombophlebitis. Monitor serum electrolytes, including potassium, phosphate, and magnesium, as supplementation may be needed. Contains chloride and acetate to buffer; avoid in patients with metabolic alkalosis. Contraindicated in hepatic coma, anuria, or inborn errors of amino acid metabolism. Infuse via infusion pump; do not add medications directly. |
| Patient Advice | This solution provides protein building blocks and must be given into a large vein. · You may have blood tests regularly to check your kidney function, liver function, and blood sugars. · Report any signs of infection at the IV site, such as redness, swelling, or pain. · Tell your healthcare provider if you experience nausea, vomiting, or confusion. · Do not stop or adjust the infusion rate on your own. |